Clinical trials consume the majority of most biotechs’ spending, and a trial budget that is wrong by thirty percent can mean running out of money before you reach the data that would have raised your next round. Yet trial budgeting is often done badly, with optimistic assumptions and no allowance for the things that reliably go wrong. Here is how to build a realistic clinical trial budget, what actually drives the cost, and where budgets most often break.
What actually drives trial cost
Trial costs are dominated by a few factors, and understanding them tells you where to focus. Number of patients is the most obvious driver, since most costs scale with enrollment. Number of sites matters greatly, because each site carries startup costs, contracting, training, and ongoing monitoring whether or not it enrolls well. Trial duration drives cost directly, as every additional month means more monitoring, more project management, and more overhead. Protocol complexity, the number of visits, procedures, assessments, and endpoints, multiplies per-patient cost. Therapeutic area matters enormously, since an oncology trial with complex imaging and biomarker work costs far more per patient than a simple study. And geography affects both site costs and the overhead of operating across regions.
The main budget categories
- Site costs, including per-patient payments to investigators, site startup fees, and site management, typically the largest single block.
- CRO fees, covering project management, monitoring, data management, biostatistics, and medical writing, which scale with duration and complexity.
- Monitoring, which is expensive and driven by visit frequency and the amount of source data verification your approach requires.
- Laboratory and central services, including central labs, bioanalysis, imaging, and specialized assessments, which can be substantial in biomarker-heavy trials.
- Technology, including your data capture system, randomization, patient-facing tools, and their setup.
- Drug supply, covering manufacturing, packaging, labeling, distribution, and comparator drug if needed, which is easy to underestimate.
- Internal costs, your own team’s time, which is real and frequently omitted.
- Regulatory and ethics submissions and fees across every country and site.
Where budgets blow up
The overruns are remarkably predictable. Slow enrollment is the biggest killer: if recruitment takes twice as long, you pay for a longer trial across every category, and this single failure drives more overruns than anything else. Protocol amendments are costly, since each one can require re-approval, retraining, system changes, and sometimes re-consenting, and most trials have several. Adding sites to rescue enrollment is expensive, because you pay full startup costs for sites that may contribute few patients. Underestimating site startup time extends the timeline. Screen failures inflate cost, since you pay to screen patients who never enroll, and a high screen failure rate can wreck a budget built on enrolled-patient assumptions. And scope creep, adding assessments or endpoints, quietly multiplies per-patient cost.
How to build a realistic budget
Build it bottom-up from your protocol, costing each visit, procedure, and assessment per patient, then scaling by enrollment and adding site, CRO, and central costs. Use realistic enrollment assumptions, ideally grounded in actual data from comparable trials rather than optimism, because this assumption drives everything. Model your screen failure rate explicitly rather than budgeting only for enrolled patients. Build in contingency, and be honest that ten percent is usually not enough for a first-time sponsor in a competitive indication. Include your own internal costs. And run the budget against a slow-enrollment scenario, because knowing what happens to your cash if recruitment takes fifty percent longer is far more useful than a single optimistic number.
Managing the budget once you are running
A budget is a live document. Track actuals against plan monthly, watch enrollment against forecast obsessively since it drives everything else, and be disciplined about scope, because every added assessment has a cost multiplied by every patient. Negotiate your CRO contract carefully, understanding what is in scope and how change orders will be priced, since change orders are where budgets quietly erode. And communicate honestly with your board about the range of outcomes rather than presenting a single confident number, because in trials, the range is the truth.
The bottom line
A realistic clinical trial budget starts from the protocol, is built bottom-up, uses honest enrollment and screen-failure assumptions, includes your internal costs, and carries genuine contingency. The overruns that kill programs are predictable, slow enrollment above all, followed by amendments, rescue sites, and scope creep, which means the best budgeting discipline is to model those scenarios before they happen rather than discover them mid-trial. Budget for the trial you will actually run, not the one you hope for, and you protect the runway that keeps your company alive.
Negotiating the CRO contract
Because CRO fees are among the largest line items in a trial budget and the place where costs most often escalate, the contract deserves real attention rather than being treated as paperwork after the selection. The key concept is scope: the contract defines what the CRO will do for the agreed price, and anything outside that scope becomes a change order, priced after you have already committed and lost most of your leverage. Change orders are where trial budgets quietly bleed, and they are frequently a larger source of overrun than the original quote suggests. Protecting yourself means several things. Define the scope carefully and realistically at the outset, including assumptions about the number of sites, the enrollment period, the number of monitoring visits, and the trial’s duration, because these assumptions drive the price and any change to them triggers a change order. Understand explicitly what is excluded. Negotiate how change orders will be priced before you need one, so you are not negotiating from a weak position mid-trial. Pay attention to the assumptions the CRO has built into their bid, since an optimistic enrollment assumption in the contract means an inevitable change order when reality intervenes. And model what happens to your costs if the trial runs six months longer than planned, since that is a likely scenario and you should know its financial consequence before you sign, not after. A well-negotiated contract with realistic assumptions and clear change-order terms will not eliminate overruns, but it converts them from unpleasant surprises into manageable, anticipated variations, which is the difference between a budget that flexes and one that breaks.
The bottom line, restated
A trial budget is a forecast, and forecasts in clinical development are wrong in predictable directions: enrollment is slower, amendments are more numerous, and screen failures are higher than anyone plans for. Build the budget bottom-up from the protocol, use honest rather than hopeful assumptions, model the slow-enrollment scenario explicitly, carry real contingency, and negotiate the CRO contract with change orders in mind. Then manage it actively, watching enrollment above all, because that single variable drives more of your cost than anything else and gives you the earliest warning that your budget is drifting.
Watch enrollment above all
If you monitor one thing after the trial starts, monitor enrollment against forecast, weekly. It is the leading indicator of nearly every budget problem you will face, because a trial running behind on recruitment will cost more in monitoring, project management, site payments, and overhead across every remaining month. Catching a recruitment shortfall early gives you options, adding sites, revisiting eligibility, adjusting strategy, while catching it late leaves you with expensive rescue measures and a budget already broken. Enrollment is the number that governs your trial’s economics, and it deserves obsessive attention.
To find CROs and service providers for your trial, browse the BioMed Nexus CRO directory, and see our related guides on choosing a CRO and managing biotech cash and runway.
Frequently asked questions
What drives clinical trial costs?
The biggest drivers are the number of patients, the number of sites (each carries startup, contracting, training and monitoring costs regardless of enrollment), trial duration, protocol complexity (visits, procedures, assessments), therapeutic area (oncology trials with imaging and biomarkers cost far more per patient), and geography.
Why do clinical trial budgets go over?
Slow enrollment is the biggest cause, because a trial that takes twice as long costs more across every category. Other common causes are protocol amendments, which require re-approval, retraining and system changes; adding rescue sites at full startup cost; underestimating site startup time; high screen failure rates; and scope creep from added assessments.
How do I build a realistic clinical trial budget?
Build bottom-up from the protocol, costing each visit and procedure per patient, then scale by enrollment and add site, CRO, central lab, technology and drug supply costs. Use realistic enrollment assumptions grounded in comparable trials, model screen failure explicitly, include your own internal costs, carry genuine contingency, and stress-test against a slow-enrollment scenario.
